Indivior Pharmaceuticals (INDV) Tax Provisions (2024 - 2026)

Indivior Pharmaceuticals' Tax Provisions history runs 3 years deep, the most recent figure standing at $26.0 million for Q1 2026.

• In Q1 2026, Tax Provisions rose 136.36% year-over-year to $26.0 million; the TTM figure through Mar 2026 stood at $44.0 million (up 238.46% YoY), while the FY2025 annual figure was $29.0 million, up 123.08% from the prior year.
• Tax Provisions was $26.0 million for Q1 2026 at Indivior Pharmaceuticals, up from -$21.0 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $44.0 million in Q2 2025 to a low of -$23.0 million in Q2 2024.
• Historically, Tax Provisions has averaged $7.6 million across 3 years, with a median of $11.0 million in 2024.
• Biggest YoY gain for Tax Provisions was 291.3% in 2025; the steepest drop was 223.53% in 2025.
• A 3-year view of Tax Provisions shows it stood at $17.0 million in 2024, then plunged by 223.53% to -$21.0 million in 2025, then surged by 223.81% to $26.0 million in 2026.
• The last three Tax Provisions figures came in at $26.0 million (Q1 2026), -$21.0 million (Q4 2025), and -$5.0 million (Q3 2025), per Business Quant data.